Hepatitis B News and Research

Latest Hepatitis B News and Research

Biomagnetics accepts Los Alamos National Labs' optical biosensor for disease diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world's first integrated optical biosensor for disease diagnosis.

27 Apr 2011

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

27 Apr 2011

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Vertex pharmaceuticals jumped 10 percent in value on the Nasdaq after U.S. regulators FDA said the company’s experimental hepatitis C drug cures more patients than current therapies.

26 Apr 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra’s drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (“NT Life”), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Supreme Court to weigh drug confidentiality laws

Marketing to doctors using prescription records bearing their names is an increasingly contentious practice, with three states, Maine, New Hampshire and Vermont, in the vanguard of enacting laws to limit the uses of a doctor's prescription records for marketing.

25 Apr 2011

Ahead of Immunization Week, WHO calls for countries to come together to control measles outbreak in Europe

WHO is urging countries in Europe to join together to help control the measles outbreak that has grown to more than 6,500 cases in 33 countries and the potential for worsening outbreaks "in the days ahead as people travel during the Easter holidays," U.N. News Centre reports.

25 Apr 2011

Echosens's Vibration Controlled Transient Elastography stands out at 46th EASL Congress

On the occasion of the 46th Congress of the European Association for the Study of the Liver, the VCTE(TM) (Vibration Controlled Transient Elastography) from Echosens stood out as a leading technique in the field. It is the only technique able to measure elasticity at a predetermined, controlled frequency (50 Hz), which is essential because elasticity increases as frequency increases.

22 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Researchers discover new compound to fight against shingles

Researchers at the University of Georgia and Yale University have discovered a compound with the potential to be more effective than existing agents in treating the very painful blisters known as shingles-a condition that affects up to 30 percent of Americans, mostly elderly, and for which no specific treatment exists.

22 Apr 2011

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Six-and-a-half weeks after receiving the first hand transplant in the western United States, Emily Fennell is becoming so accustomed to her new right hand that she barely remembers when she didn't have one.

21 Apr 2011

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Merck and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.

21 Apr 2011

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.

21 Apr 2011

Biomagnetics signs agreement with LANL to develop validated TB biomarker assay

Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and related technology for detecting HIV, hepatitis, tuberculosis, cholera and malaria, and other innovative technologies, today announced it has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and development agreement (CRADA) executed in 2010 between the two organizations.

21 Apr 2011

BIOTECH Development Partners provides funds to Biomagnetics

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has begun receiving funds from a biotech-oriented investment group called BIOTECH Development Partners, LLC.

20 Apr 2011

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

On the heels of Centers for Disease Control announcement earlier today that an ongoing study of the use of Gilead's top selling AIDS treatment, Truvada, as a possible form of pre-exposure prophylaxis for HIV prevention in women is being abruptly halted because the, "…trial could not demonstrate efficacy," the AIDS Healthcare Foundation renewed its call on Gilead Sciences to slow its fast track pursuit of its application for FDA approval of use of its AIDS drug as a possible form of HIV prevention.

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Quest Diagnostics launches AccuType IL28B test for HCV

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability of its AccuType® IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection.

From Quest Diagnostics 18 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

Hepatitis B News and Research

Latest Hepatitis B News and Research

Biomagnetics accepts Los Alamos National Labs' optical biosensor for disease diagnosis

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Study: HIV infection linked to increased risk of heart failure

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Supreme Court to weigh drug confidentiality laws

Ahead of Immunization Week, WHO calls for countries to come together to control measles outbreak in Europe

Echosens's Vibration Controlled Transient Elastography stands out at 46th EASL Congress

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Researchers discover new compound to fight against shingles

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Biomagnetics signs agreement with LANL to develop validated TB biomarker assay

BIOTECH Development Partners provides funds to Biomagnetics

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Quest Diagnostics launches AccuType IL28B test for HCV

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis B News and Research

Latest Hepatitis B News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in